Customer Care BPO

Global Cutaneous and Systemic Leishmaniasis Market to Reach US$393.1 Million by 2030

The global market for Cutaneous and Systemic Leishmaniasis estimated at US$354.8 Million in the year 2024, is expected to reach US$393.1 Million by 2030, growing at a CAGR of 1.7% over the analysis period 2024-2030. Pentavalent Antimonials Drug Class, one of the segments analyzed in the report, is expected to record a 1.4% CAGR and reach US$220.5 Million by the end of the analysis period. Growth in the Antifungals Drug Class segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$96.7 Million While China is Forecast to Grow at 3.2% CAGR

The Cutaneous and Systemic Leishmaniasis market in the U.S. is estimated at US$96.7 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$72.1 Million by the year 2030 trailing a CAGR of 3.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.0% CAGR.

Global Cutaneous and Systemic Leishmaniasis Market – Key Trends & Drivers Summarized

Why Is Leishmaniasis a Critical Focus Area in Global Infectious Disease Management?
Cutaneous and systemic leishmaniasis represent two of the most challenging neglected tropical diseases, caused by protozoan parasites of the Leishmania genus, transmitted through the bite of infected sandflies. Cutaneous leishmaniasis primarily affects the skin, causing ulcers and disfiguring lesions, while systemic or visceral leishmaniasis—also known as kala-azar—is far more severe, impacting internal organs such as the liver, spleen, and bone marrow and can be fatal if left untreated. Both forms of the disease disproportionately affect populations in low- and middle-income regions, particularly in parts of South Asia, Africa, Latin America, and the Middle East.

Despite being endemic to over 90 countries, leishmaniasis remains underdiagnosed and underfunded. Poor sanitation, climate change, human migration, and deforestation are accelerating its transmission. The increasing incidence of treatment-resistant strains, coinfections with HIV, and the limited availability of effective, safe, and affordable therapies underscore the urgency for improved diagnostic tools, novel therapeutics, and preventive strategies. As public health agencies and global organizations intensify focus on controlling neglected tropical diseases, the medical and pharmaceutical sectors are responding with renewed R&D into innovative leishmaniasis treatments.

What Therapeutic Approaches and Diagnostic Advancements Are Reshaping Disease Management?
Current treatment options for cutaneous and systemic leishmaniasis include antimonial compounds, amphotericin B, miltefosine, and paromomycin. However, many of these therapies have significant limitations, including toxicity, lengthy treatment durations, parenteral administration, and variable efficacy across parasite species. In systemic leishmaniasis, liposomal amphotericin B has become a preferred option in certain regions due to better safety profiles, though access remains limited by cost and logistical barriers. Combination therapies are being explored to enhance efficacy, reduce resistance, and shorten treatment regimens.

On the diagnostic front, traditional parasitological methods are being supplemented with molecular diagnostics (e.g., PCR-based assays) and rapid antigen detection tests, improving early-stage diagnosis and treatment monitoring. In cutaneous forms, dermal smear microscopy and histopathological examinations remain widely used, though newer point-of-care diagnostic kits are gaining ground in rural health systems. Research is also focused on identifying vaccine candidates and developing novel drug delivery systems such as liposomal formulations and transdermal patches that offer improved targeting and reduced side effects.

Which Regions and Patient Segments Are Most Affected by the Disease Burden?
The highest prevalence of cutaneous leishmaniasis is found in Afghanistan, Syria, Brazil, Iran, and Pakistan, where social instability, vector proliferation, and limited healthcare infrastructure exacerbate disease spread. Visceral leishmaniasis remains endemic in India, Sudan, Ethiopia, and Bangladesh, particularly affecting impoverished rural populations with low access to healthcare. Children, immunocompromised individuals, and those co-infected with HIV are particularly vulnerable to visceral forms of the disease, with higher fatality rates and poorer treatment outcomes.

Refugee populations, labor migrants, and residents of conflict zones are increasingly affected due to the collapse of disease control programs and rising exposure to sandfly habitats. Urban expansion into forested or agricultural areas is also increasing the human-vector interface, further driving transmission. Mass drug administration programs, community awareness campaigns, and vector control initiatives remain critical in these high-burden areas, although challenges in funding, diagnostics, and logistics continue to limit impact.

What Factors Are Driving Growth in the Cutaneous and Systemic Leishmaniasis Treatment Market?
The growth in the cutaneous and systemic leishmaniasis market is driven by several interrelated public health, pharmaceutical, and environmental factors. Rising global attention to neglected tropical diseases and increasing funding from non-governmental organizations and public health agencies are fueling research into more effective and accessible treatment options. The expanding pipeline of drug candidates—including oral therapies, nano-formulations, and immunomodulators—is introducing new avenues for safer, shorter, and more scalable treatment regimens.

Growing support for public-private partnerships is enabling collaborative drug development, distribution, and data-sharing initiatives to address endemic needs. The intensifying intersection of leishmaniasis with other public health issues, such as HIV and malnutrition, is driving integrated healthcare responses and broader screening initiatives. Lastly, innovations in vector surveillance, climate-based risk mapping, and mobile diagnostics are improving early detection and intervention capabilities. These dynamics collectively underscore a growing commitment to eliminating leishmaniasis as a public health threat and expanding market opportunities for therapeutic and diagnostic innovation.

SCOPE OF STUDY:

The report analyzes the Cutaneous and Systemic Leishmaniasis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Class (Pentavalent Antimonials Drug Class, Antifungals Drug Class, Anti-Lesihmanial / Antimicrobials Drug Class); Administration Route (Oral Route, Injectable Route, Topical Route); Indication (Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication, Visceral Leishmaniasis Indication); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Distribution Channel)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Albert David Ltd.
• Bayer AG
• Biocon Limited
• BioLineRx Ltd.
• Bristol-Myers Squibb
• Camurus AB
• DNDi
• Eisai Co., Ltd.
• Endo Pharmaceuticals
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Janssen Global Services
• Jubilant Life Sciences
• Knight Therapeutics Inc.
• Novartis AG
• Pfizer Inc.
• Protalix BioTherapeutics
• Sanofi
• Takeda Pharmaceutical
• United Biotech Pvt. Ltd.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more